Please check your internet connection and try again.
# Mylot%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at
## Overview
Mylot%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at is a brand name for [drug name, e.g., trifluridine/tipiracil]. It is a combination medication used for the treatment of [indication, e.g., metastatic gastric or gastroesophageal junction adenocarcinoma].
## Primary Indications
* [Specific indication 1, e.g., Metastatic gastric or gastroesophageal junction adenocarcinoma in patients refractory to standard chemotherapy.]
## Adult Dosing
* **Typical Dose:** [Specific dose, e.g., 35.4 mg/m² trifluridine and 10 mg/m² tipiracil administered orally twice daily.]
* **Maximum Dose:** [Specify maximum dose if applicable. For example, if there's a mg/kg limit or a dose capping based on body surface area.]
## Pediatric Dosing
* Information regarding pediatric dosing for Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at is not well-established or may depend on specific clinical scenarios. Consult specialized pediatric oncology resources.
## Dose Adjustments
* **Renal Impairment:** Dose adjustments may be necessary. Consult specific prescribing information or local protocol for guidance in patients with moderate to severe renal impairment.
* **Hepatic Impairment:** Dose adjustments may be necessary. Consult specific prescribing information or local protocol for guidance in patients with hepatic impairment.
* **Hematologic Toxicity:** Dose modifications are typically required based on the nadir of neutrophil counts, hemoglobin, and platelet counts. Specific guidelines are available in the prescribing information.
* **Non-hematologic Toxicity:** Dose reduction may be necessary for Grade 3 or 4 non-hematologic toxicities.
## Contraindications
* [List specific contraindications, e.g., Hypersensitivity to trifluridine/tipiracil or any of its components.]
## Adverse Effects
* **Common:** [List common adverse effects, e.g., Neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, decreased appetite, stomatitis.]
* **Serious:** [List serious adverse effects, e.g., Severe myelosuppression, febrile neutropenia, severe gastrointestinal toxicity, cardiac events.]
## Key Drug Interactions
* [List significant drug interactions, e.g., Drugs that inhibit or induce CYP enzymes, drugs that affect bone marrow function.] Specific interactions and management strategies should be reviewed.
## Monitoring
* **Hematologic:** Regular monitoring of complete blood counts (CBC) with differential and platelet counts is essential, especially prior to each cycle and as clinically indicated.
* **Renal and Hepatic Function:** Monitor periodically.
* **Adverse Events:** Monitor for signs and symptoms of common and serious adverse effects.
## Clinical Pearls
* Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at administration requires careful attention to potential myelosuppression.
* Educate patients on the importance of reporting any signs of infection, bleeding, or severe gastrointestinal distress immediately.
* Consider prophylactic antiemetics and antidiarrheals as per institutional guidelines.
***
*Disclaimer: This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
